34 related articles for article (PubMed ID: 20811894)
1. Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study.
Nguyen HT; Do KH; Le NB; Tran T
Cancer Manag Res; 2022; 14():2825-2837. PubMed ID: 36164467
[TBL] [Abstract][Full Text] [Related]
2. Tongue conservation treatment for oral tongue squamous cell carcinoma with induction chemotherapy, surgery, and risk-adapted adjuvant therapy: A phase II trial.
Lee TL; Wei PY; Yang MH; Chang PM; Wang LW; Tai SK
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1456. PubMed ID: 34051137
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial.
Ahmadzadeh A; Seyedian SS; Valizadeh A; Soleimani M; Nazari P; Hamidi H
Asian Pac J Cancer Prev; 2020 Mar; 21(3):727-732. PubMed ID: 32212800
[TBL] [Abstract][Full Text] [Related]
4. Recent progress of chemotherapy and biomarkers for gastroesophageal cancer.
Maeda O; Ando Y
World J Gastrointest Oncol; 2019 Jul; 11(7):518-526. PubMed ID: 31367271
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
Kim JH; Park SR; Ryu MH; Ryoo BY; Kim KP; Kim BS; Yoo MW; Yook JH; Kim BS; Kim J; Byeon SJ; Kang YK
Cancer Res Treat; 2018 Apr; 50(2):518-529. PubMed ID: 28546521
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Cho H; Ryu MH; Kim KP; Ryoo BY; Park SR; Kim BS; Lee IS; Kim HS; Yoo MW; Yook JH; Oh ST; Kim BS; Kang YK
Gastric Cancer; 2017 Nov; 20(6):970-977. PubMed ID: 28303362
[TBL] [Abstract][Full Text] [Related]
7. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study.
Maeda O; Matsuoka A; Miyahara R; Funasaka K; Hirooka Y; Fukaya M; Nagino M; Kodera Y; Goto H; Ando Y
World J Gastroenterol; 2017 Feb; 23(6):1090-1097. PubMed ID: 28246483
[TBL] [Abstract][Full Text] [Related]
8. Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines.
Wang TY; Chen WM; Yang LY; Chen CY; Chou WC; Chen YY; Chen CC; Lee KD; Lu CH
Support Care Cancer; 2016 Nov; 24(11):4697-703. PubMed ID: 27329415
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer.
Yoon S; Yoo C; Ryu MH; Kang MJ; Ryoo BY; Park SR; Yook JH; Oh ST; Yoo MW; Kim BS; Kang YK
Gastric Cancer; 2017 Jan; 20(1):182-189. PubMed ID: 26661592
[TBL] [Abstract][Full Text] [Related]
10. Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution.
Koo DH; Ryu MH; Ryoo BY; Seo J; Lee MY; Chang HM; Lee JL; Lee SS; Kim TW; Kang YK
Gastric Cancer; 2015 Apr; 18(2):346-53. PubMed ID: 24832201
[TBL] [Abstract][Full Text] [Related]
11. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Gómez-Martin C; Sánchez A; Irigoyen A; Llorente B; Pérez B; Serrano R; Safont MJ; Falcó E; Lacasta A; Reboredo M; Aparicio J; Dueñas R; Muñoz ML; Regueiro P; Sanchez-Viñes E; López RL
Clin Transl Oncol; 2012 Sep; 14(9):689-97. PubMed ID: 22855151
[TBL] [Abstract][Full Text] [Related]
12. Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus.
Park JW; Yoon J; Cho CK; Lee YW; Yoo HS
Chin J Integr Med; 2014 Jan; 20(1):49-55. PubMed ID: 22610951
[TBL] [Abstract][Full Text] [Related]
13. Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer.
Jo JC; Lee JL; Ryu MH; Chang HM; Kim M; Lee HJ; Kim HS; Shin JG; Kim TW; Kang YK
Br J Cancer; 2012 May; 106(10):1591-7. PubMed ID: 22516947
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies for gastric cancer: current status.
Yoong J; Michael M; Leong T
Drugs; 2011 Jul; 71(11):1367-84. PubMed ID: 21812503
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
Kang YK; Ryu MH; Yoo C; Chang HM; Yook JH; Oh ST; Kim BS; Kim TW
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1435-43. PubMed ID: 20811894
[TBL] [Abstract][Full Text] [Related]
16. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I
Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.
Sym SJ; Chang HM; Ryu MH; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Ann Surg Oncol; 2010 Apr; 17(4):1024-32. PubMed ID: 19941081
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
19. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen.
Ajani JA
Cancer; 2008 Sep; 113(5):945-55. PubMed ID: 18623382
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]